Beta Bionics said it plans to launch its first insulin patch pump, Mint, by end of Q2 2027, pending FDA clearance, after initial FDA feedback on its 510(k) application and manufacturing scale-up progress. Mint would work with its interoperable automated glycemic controller, using glucose sensor data to adjust insulin delivery. It targets a 3-day wear time and a 200-unit reservoir. Shares rose more than 11% to $11.82.
General Electric Co has acquired a significant new position in BETA Technologies Inc (NYSE:BETA), purchasing over 22.8 million shares valued at approximately $644.96 million. This investment positions BETA Technologies as General Electric Co's largest holding, constituting 98.5% of its portfolio. The article also details recent insider stock sales, analyst rating changes with a consensus of "Moderate Buy," and BETA Technologies' recent financial performance.
Beta Technologies Inc. (BETA) has entered oversold territory with a Relative Strength Index (RSI) of 29.8, indicating potential undervaluation due to recent heavy selling. This could be an opportunity for bullish investors to consider entry points. The stock's current price of $17.45 is near its 52-week low of $15.61, significantly below its 52-week high of $39.50.
